Predicting pathological response to neoadjuvant chemotherapy in breast cancer patients based on imbalanced clinical data

2018 ◽  
Vol 22 (5-6) ◽  
pp. 1039-1047 ◽  
Author(s):  
Ting Gao ◽  
Yaguang Hao ◽  
Haipeng Zhang ◽  
Lina Hu ◽  
Hongzhi Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Clinical Data ◽  
Pathological Response ◽  
Breast Cancer Patients ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging

2018 ◽  
Vol 225 ◽  
pp. 175-180 ◽  
Author(s):  
Hiroshi Kaise ◽  
Fumika Shimizu ◽  
Kohei Akazawa ◽  
Yoshie Hasegawa ◽  
Jun Horiguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pathological Response ◽  
Breast Cancer Patients ◽  
Response To Neoadjuvant Chemotherapy

Predictive value of the pattern of β-catenin expression for pathological response to neoadjuvant chemotherapy in breast cancer patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12013-e12013
Author(s):  
Shereef Elsamany ◽  
Omaima Elemam ◽  
Abdullah Saeed Alzahrani ◽  
Mohammed M. Abbas ◽  
Soha Elmorsy
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Predictive Value ◽  
Pathological Response ◽  
Breast Cancer Patients ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer

2008 ◽  
Vol 26 (25) ◽  
pp. 4072-4077 ◽  
Author(s):  
Jennifer K. Litton ◽  
Ana M. Gonzalez-Angulo ◽  
Carla L. Warneke ◽  
Aman U. Buzdar ◽  
Shu-Wan Kau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pathologic Complete Response ◽  
Operable Breast Cancer ◽  
Obese Patients ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Response To Neoadjuvant Chemotherapy

Purpose To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer. Patients and Methods From May 1990 to July 2004, 1,169 patients were diagnosed with invasive breast cancer at M. D. Anderson Cancer Center and received NC before surgery. Patients were categorized as obese (BMI ≥ 30 kg/m2), overweight (BMI of 25 to < 30 kg/m2), or normal/underweight (BMI < 25 kg/m2). Logistic regression was used to examine associations between BMI and pathologic complete response (pCR). Breast cancer–specific, progression-free, and overall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regression analysis. All statistical tests were two-sided. Results Median age was 50 years; 30% of patients were obese, 32% were overweight, and 38% were normal or underweight. In multivariate analysis, there was no significant difference in pCR for obese compared with normal weight patients (odds ratio [OR] = 0.78; 95% CI, 0.49 to 1.26). Overweight and the combination of overweight and obese patients were significantly less likely to have a pCR (OR = 0.59; 95% CI, 0.37 to 0.95; and OR = 0.67; 95% CI, 0.45 to 0.99, respectively). Obese patients were more likely to have hormone-negative tumors (P < .01), stage III tumors (P < .01), and worse overall survival (P = .006) at a median follow-up time of 4.1 years. Conclusion Higher BMI was associated with worse pCR to NC. In addition, its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document